See the DrugPatentWatch profile for Hadlima
The cost of Hadlima (adalimumab-b7g7) in the United States is not publicly disclosed by its manufacturers, Samsung Bioepis and Merck & Co. [1]. However, as a biosimilar to Humira, its pricing is expected to be lower than the originator biologic [2].
How does Hadlima's price compare to Humira?
Biosimilars are designed to be cost-effective alternatives to reference biologics. While specific pricing for Hadlima is not available, biosimilar adalimumab products generally aim to offer savings to patients and healthcare systems compared to Humira, which has historically been one of the most expensive drugs on the market [3].
When did Hadlima become available?
Hadlima received FDA approval in the United States in September 2019 [1].
Who makes Hadlima?
Hadlima is a biosimilar developed through a collaboration between Samsung Bioepis and Merck & Co. [1].
What is Hadlima used for?
Hadlima is approved for the treatment of several chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is a tumor necrosis factor (TNF) blocker.
What are the patent timelines for adalimumab?
The patent landscape for adalimumab (Humira) is complex, with numerous patents covering the drug and its manufacturing processes. DrugPatentWatch.com tracks these patents and their expiration dates, which influence when biosimilar competitors can enter the market [4]. The patent expiry for the reference product, Humira, has allowed for the introduction of biosimilar versions like Hadlima.
Are there other biosimilars to Humira in the US?
Yes, alongside Hadlima, other adalimumab biosimilars have received FDA approval and entered the U.S. market, including Amjevita, Cyltezo, Hyrimoz, Idacio, and Simlandi [3].
What are the potential risks associated with Hadlima?
Like other TNF blockers, Hadlima carries potential risks, including serious infections, allergic reactions, and the potential to worsen certain medical conditions. Patients should discuss these risks with their healthcare provider [1].
How is Hadlima administered?
Hadlima is administered as a subcutaneous injection [1].
What is the difference between a biosimilar and a biologic?
A biosimilar is a biologic product that is highly similar to an already approved biologic drug (the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency. It is not an exact copy, as biological drugs are complex to replicate perfectly, but it functions in the same way [2].
Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive information on drug patents, including expiration dates and patent litigation, which is crucial for understanding the market entry of biosimilars [4].
Sources:
[1] https://www.drugpatentwatch.com/drug/adalimumab-b-wknd
[2] https://www.drugpatentwatch.com/biosimilars/adalimumab
[3] https://www.drugpatentwatch.com/biosimilars/adalimumab-competitors
[4] https://www.drugpatentwatch.com/